Vertex Pharmaceuticals Incorporated – Biotech Stocks To Buy Right Now
Vertex Pharmaceutical is a biotech company based out of Boston. The company specializes in developing small molecule drugs following a rational drug design approach. Vertex drugs are considered to be the benchmark globally in areas like cystic fibrosis. Vertex has a solid pipeline of medicines in cancer, inflammatory diseases, influenza, pain, and other rate diseases. Its long-term prospects look bright. Investors looking for the best biotech stocks to buy right now may want to consider Vertex Pharmaceuticals for its strong focus on research and product development.
More About Vertex Pharmaceuticals
Vertex Pharmaceuticals is credited with being one of the first biotech companies to follow the rational drug design strategy rather than the combinatorial chemistry strategy. The company was founded in the year 1989 by Joshua Boger and Kevin Kinsella. It developed a promising product pipeline in its initial years, and by 2004, it was serving the inflammatory, viral infection, cancer, and autoimmune disorder markets. The company grew over the next few years and had over 2,500 employees by 2019. The growth of the company has not gone unnoticed, as Vertex has been ranked several times among the top 15 best-performing companies by Standard & Poor’s 500. Some of the most well-known drugs of Vertex Pharmaceuticals include Orkambi, Trikafta, Kalydeco, and Symdeko. If you are looking for biotech stocks to buy right now, then Vertex Pharmaceuticals deserves a look-in.
Vertex Pharmaceutical’s stock closed at $211 on March 5th, 2021. The stock is down 1.11% over the preceding 30 days. Vertex Pharmaceuticals wasn’t paying a dividend as of March 2021. On a 1-year basis, the stock is down 9%. However, on a longer-term basis (we define longer-term as five years), the stock is up more than 145% and had been doing quite well until July of 2020. The market capitalization of Vertex Pharmaceuticals was over $55 billion as of March 5th, 2020.